Real Estate [ 13/13 ] | Real Estate Services [ 128/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -0.14 Decreased by -146.59% | - |
| Aug 14, 23 | -0.25 Decreased by -988.6% | - |
| May 22, 23 | -0.28 Decreased by -1.29 K% | - |
| Mar 30, 23 | -0.24 Decreased by -709% | - |
| Nov 14, 22 | -0.06 Decreased by -179% | - |
| Aug 5, 22 | -0.02 Increased by +24% | - |
| May 11, 22 | -0.02 Increased by +33.33% | - |
| Mar 30, 22 | -0.03 Increased by +25% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 331.29 K Increased by +4.38% | -1.49 M Increased by +83.93% | Decreased by -448.27% Increased by +84.6% |
| Jun 30, 23 | 306.9 K Increased by +5.53% | -2.54 M Increased by +0.78% | Decreased by -828.7% Increased by +5.98% |
| Mar 31, 23 | 296.17 K Decreased by -0.49% | -5.77 M Decreased by -186.46% | Decreased by -1.95 K% Decreased by -187.88% |
| Dec 31, 22 | 296.33 K Decreased by -11.33% | -2.6 M Decreased by -11.47% | Decreased by -878.11% Decreased by -25.72% |
| Sep 30, 22 | 317.39 K Decreased by -34.8% | -9.24 M Decreased by -356.43% | Decreased by -2.91 K% Decreased by -600.01% |
| Jun 30, 22 | 290.82 K Increased by +3.78% | -2.56 M Decreased by -8.39% | Decreased by -881.43% Decreased by -4.45% |
| Mar 31, 22 | 297.63 K Increased by +2.71% | -2.01 M Increased by +14.91% | Decreased by -676.72% Increased by +17.16% |
| Dec 31, 21 | 334.2 K Decreased by -26.48% | -2.33 M Increased by +24.71% | Decreased by -698.46% Decreased by -2.4% |
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.